Oct 28, 2023 · Here, we report the pro-tumorigenic properties of the crosstalk between intestinal tuft cells and type 2 innate lymphoid cells (ILC2) that is evolutionarily optimized for epithelial remodeling in...

Mar 12, 2025 · Tuft cell IL-17RB is crucial for restraining IL-25 bioavailability, preventing excessive tonic ILC2 stimulation due to basal Il25 expression.

Jun 3, 2022 · Colorectal cancer (CRC) patients with higher tumor IL25 expression had reduced survival and increased IL-25R–expressing tumor-resident ILC2s and myeloid-derived suppressor cells (MDSCs) associated with impaired antitumor responses.

Nov 1, 2023 · IL-33 activates ILC2 and CD8 + T cells to inhibit tumor growth, and DCLK1 can regulate M1/M2 macrophage polarization and PD-L1 expression. In colorectal cancer, IL-25 activates ILC2 to inhibit Th1 and anti-tumor T-cell immunity, while DCLK1 promotes the accumulation of MDSC via CXCR2-CXCL1 binding.

Tuft cells—rare solitary chemosensory cells in mucosal epithelia—are undergoing intense scientific scrutiny fueled by recent discovery of unsuspected connections to type 2 immunity.

Jun 3, 2022 · This pathway is initiated by the tuft cell—a rare, chemosensory, secretory epithelial cell that senses an array of luminal signals at barrier surfaces and then assumes the sole responsibility to produce IL-25—another canonical cytokine that activates ILC2s.

Here, we evaluated the immunomodulatory role of chemosensory signaling in metaplastic tuft cells (MTCs) by analyzing the role of GNAT3, a gustatory pathway G-protein expressed by MTCs, during PDA progression.

Jun 3, 2022 · In the intestine, IL-25 is expressed by tuft cells and is a key factor in ILC2 activation in protective immune responses to parasitic helminth infections (1–4), facilitating the inter-face between innate and adaptive immunity, and promoting tissue repair after damage.

Dec 1, 2024 · C D-sHDL leads to MDSC infiltration and treatment resistance of orthotopic CRC tumors. MDSC recruitment is enhanced by succinate-activating tuft cells after chemotherapy. Cabozantinib reduces C D-sHDL-induced succinate release by inhibiting its synthesis.

Here, we report the pro-tumorigenic properties of the crosstalk between intestinal tuft cells and type 2 innate lymphoid cells (ILC2) that is evolutionarily optimized for epithelial remodeling in response to helminth infection.